32. T. Umeda et al., "Kinetics of the Thermal Transition of Carbamazepine Polymorphic Forms in the Solid State," Yakugaku Zasshi
104 (7), 786–792 (1984).
33. M.M.J. Lowes et al., "Physicochemical Properties and X-ray Structural Studies of the Trigonal Polymorph of Carbamazepine,"
J. Pharm. Sci.
76 (9), 744–752 (1987).
34. F.U. Krahn and J.B. Mielck, "Relations between Several Polymorphic Forms and the Dihydrate of Carbamazepine," Pharm. Acta Helv.
62 (9), 247–254 (1987).
35. J. Dugué et al., "Polymorphism of Carbamazepine: Solid-State Studies on Carbamazepine Dihydrate," Pharm. Acta Helv.
66 (11), 307–310 (1991).
36. L.E. McMahon et al, "Characterization of Dihydrates Prepared from Carbamazepine Polymorphs," J. Pharm. Sci.
85 (10), 1064–1069 (1996).
37. I. Katzhendler, R. Azoury, and M. Friedman, "Crystalline Properties of Carbamazepine in Sustained Release Hydrophilic
Matrix Tablets Based on Hydroxypropyl Methylcellulose," J. Control. Release
54 (1), 69–85 (1998).
38. Y. Kobayashi et al., "Physicochemical Properties and Bioavailability of Carbamazepine Polymorphs and Dihydrate," Int. J. Pharm.
193 (2), 137–146 (2000).
39. C. Rustichelli et al., "Solid-State Study of Polymorphic Drugs: Carbamazepine," J. Pharm. Biomed. Anal.
23 (1), 41–54 (2000).
40. R. Nair, S. Gonen, and S.W. Hoag, "Influence of Polyethylene Glycol and Povidone on the Polymorphic Transformation and
Solubility of Carbamazepine," Int. J. Pharm.
240 (1–2), 11–22 (2002).
41. Y. Yoshihashi, E. Yonemochi, and K. Terada, "Estimation of Initial Dissolution Rate of Drug Substance by Thermal Analysis:
Application for Carbamazepine Hydrate," Pharm. Dev. Technol.
7 (1), 89–95 (2002).
42. A. Cvetkovskii et al., "Thermal Properties of Binary Mixtures of β-Cyclodextrin with Carbamazepine Polymorphs," J. Therm. Anal. Calorim.
68 (2), 669–678 (2002).
43. A. L. Grzesiak et al., "Comparison of the Four Anhydrous Polymorphs of Carbamazepine and the Crystal Structure of Form
I," J. Pharm. Sci.
92 (11), 2260–2271 (2003).
44. R. Hilfiker et al., "Polymorphism—Integrated Approach from High-Throughput Screening to Crystallization Optimization,"
J. Therm. Anal. Calorim.
73 (2) 429–440 (2003).
45. S.G. Fleischman et al., "Crystal Engineering of the Composition of Pharmaceutical Phases: Multiple-Component Crystalline
Solids Involving Carbamazepine," Cryst. Growth Des.
3 (6), 909–919 (2003).
46. N. Rodríguez-Hornedo and D. Murphy, "Surfactant-Facilitated Crystallization of Dihydrate Carbamazepine during Dissolution
of Anhydrous Polymorph," J. Pharm. Sci.
93 (2), 449–460 (2004).
47. H.G. Brittain, "Fluorescence Studies of the Transformation of Carbamazepine Anhydrate Form III to Its Dihydrate Phase,"
J. Pharm. Sci.
93 (2), 375–383 (2004).
48. C. McGregor et al., "The Use of High-Speed Differential Scanning Calorimetry (Hyper-DSC) to Study the Thermal Properties
of Carbamazepine Polymorphs," Thermochimica Acta
417 (2), 231–237 (2004).
49. A.J. Cruz Cabeza et al., "Importance of Molecular Shape for the Overall Stability of Hydrogen Bond Motifs in the Crystal
Structures of Various Carbamazepine-Type Drug Molecules," Cryst. Growth Des.
7 (1), 100–107 (2007).
50. K. Seefeldt et al., "Crystallization Pathways and Kinetics of Carbamazepine–Nicotinamide Cocrystals from the Amorphous
State by In Situ Thermomicroscopy, Spectroscopy, and Calorimetry Studies," J. Pharm. Sci.
96 (5) 1147–1158 (2007).
51. F. Tian et al., "Influence of Polymorphic Form, Morphology, and Excipient Interactions on the Disoolution of Carbamazepine
Compacts," J. Pharm. Sci.
96 (3), 584–594 (2007).
52. M. Shibata et al., "X-Ray Structural Studies and Physicochemical Properties of Cimetidine Polymorphism," J. Pharm. Sci.
72 (12), 1436–1442 (1983).
53. B. Hegedüs and S. Görög, "The Polymorphism of Cimetidine," J. Pharm. Biomed. Anal.
3 (4), 303–313 (1985).
54. S. Sudo, K. Sato, and Y. Harano, "Solubilities and Crystallization Behavior of Cimetidine Polymorphic Forms A and B,"
J. Chem. Eng. Japan
24 (2), 237–242 (1991).
55. A. M. Tudor et al., "The Applications of Near-Infrared Fourier Transform Raman Spectroscopy to the Analysis of Polymorphic
Forms of Cimetidine," Spectrochim. Acta
47A (9/10), 1389–1393 (1991).
56. E. Hädicke, F. Frickel, and A. Franke, "Die Struktur von Cimetidin (N"-Cyan-N-Methyl-N'-[2-[(5-methyl-1H-imidazol-4-yl)methylthio]
ethyl]guanidine), einem Histamin H2-Rezeptor-Antagonist," Chem. Ber.
111 (9), 3222–3232 (1978).
57. A. Bauer-Brandl, "Polymorphic Transitions of Cimetidine during Manufacture of Solid Dosage Forms," Int. J. Pharm.
140 (2), 195–206 (1996).
58. A. Bauer-Brandl et al., "Comparison of Experimental Methods and Theoretical Calculations on Crystal Energies of 'Isoenergetic'
Polymorphs of Cimetidine," J. Therm. Anal. Calorim.
57 (1), 7–22 (1999).
59. W.A. Bueno and E.G. Sobrinho, "Hydrogen Bonds in the Cimetidine Molecule," Spectrochim. Acta
51A (2), 287–292 (1995).
60. H.G. Ibrahim, F. Pisano, and A. Bruno, "Polymorphism of Phenylbutazone: Properties and Compressional Behavior of Crystals,"
J. Pharm.Sci.
66 (5) 669–673 (1977).
61. Y. Matsuda et al., "Polymorphism of Phenylbutazone by a Spray Drying Method," J. Pharm. Pharmacol.
32 (8), 579–580 (1980).
62. M.D. Tuladhar, J.E. Carless, and M.P. Summers, "Thermal Behavior and Dissolution Properties of Phenylbutazone Polymorphs,"
J. Pharm. Pharmacol.
35 (4), 208–214 (1983).
63. Y. Matsuda et al., "Physiochemical Characterization of Spray-Dried Phenylbutazone Polymorphs," J. Pharm. Sci.
73 (2), 173–179 (1984).
64. H.H. Paradies, "Structure of Phenylbutazone and Mofebutazone in the Crystalline State and in Solution," J. Pharm. Sci.
76 (12), 920–929 (1987).
65. T. Matsumoto et al., "Effect of Environmental Temperature on the Polymorphic Transformation of Phenylbutazone during
Grinding," Chem. Pharm. Bull.
36 (3), 1074–1085 (1988).
66. N. Kaneniwa, J.I. Ichikawa, and T. Matsumoto, "Preparation of Phenylbutazone Polymorphs and Their Transformation in Solution,"
Chem. Pharm. Bull.
36 (3), 1063–1073 (1988).
67. Á. Beretzky et al., "Pelletization of Needle-Shaped Phenylbutazone crystals," J. Therm. Anal. Calorim.
69 (2), 529–539 (2002).
68. T. Hosokawa et al., "Isostructurality among Five Solvates of Phenylbutazone," Cryst. Growth Des.
4 (6), 1195–1201 (2004).
69. T. Hosokawa et al., "Relationships between Crystal Structures and Thermodynamic Properties of Phenylbutazone Solvates,"
Cryst. Eng. Comm.
6 (44), 243–249 (2004).
70. N.G. Anderson, "Solvent Selection," in Practical Process Research and Development (Academic Press, New York, 1st ed., 2000), pp. 81–111.
|
